Dimerix Ltd (ASX:DXB) is preparing to take investors through the results of its Phase 2 trial results on Chronic Kidney Disease, with the ASX granting the company a trading halt to prepare.
The results will be a key inflection point for the company.
The halt will remain in place until the opening of trade on Thursday 13th July 2017, or earlier if an announcement is made to the market.